Oligonucleotides for modulating tau expression
AssigneeHoffmann-La Roche Inc.
InventorsPeter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. OLSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
Claims30
An antisense oligonucleotide of 10 to 30 nucleotides in length, which comprises a contiguous nucleotide sequence of at least 10 nucleotides in length with at least 90% complementarity, to contiguous nucleotides within position 12051 to 12111, 39562 to 39593 or 72837 to 72940 of SEQ ID NO:
- 1.
-27. (canceled)
Dependencies are inferred from the claim text.